Updates

March 5, 2021March 5, 2021
Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US

After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously ... Read more
March 3, 2021March 3, 2021
Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients

A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed patients with metastatic renal cell ... Read more
March 1, 2021March 1, 2021
Imfinzi No Longer Available in US for Advanced Bladder Cancer

After consulting with the U.S. Food and Drug Administration (FDA), AstraZeneca has announced that Imfinzi (durvalumab) — which last year failed a confirmatory Phase 3 ... Read more
February 26, 2021February 26, 2021
Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers

Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — a form of immunotherapy — ... Read more
February 24, 2021February 24, 2021
Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation emai

May 9, 2018May 9, 2018

Researchers May Now Predict Which CLL Patients Will Respond to Kymriah CAR T-Cell Therapy, Study Says

News

The absence of a specific T-cell subset may help explain why three in four patients with advanced chronic lymphocytic leukemia (CLL) fail to respond to Kymriah (tisagenlecleucel) — a CAR T-cell therapy approved for another kind of leukemia, according to researchers. ... Read more

Updates

Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US

Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients

Imfinzi No Longer Available in US for Advanced Bladder Cancer

Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers

Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer

Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Show

FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruiting

Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22

FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma

CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomas

Subscribe to our mailing list

Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show

Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumors

Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphoma

First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytruda

EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers

Bavencio Approved in EU as First-line Maintenance Therapy for Bladder Cancer

Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancer

T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer

Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy

Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Finds

EU Approval Urged for Bavencio as Maintenance Therapy for Bladder Cancer

Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancers

Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Show

Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Show

FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer

Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survival

Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer

Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancer

Researchers May Now Predict Which CLL Patients Will Respond to Kymriah CAR T-Cell Therapy, Study Says